SCHEMBL1782526

SCHEMBL1782526

c1csc(-c2cc[nH]n2)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.46
PDPK1 O15530 1/20 0.44
RAB9A P51151 1/20 0.43
ADORA2A P29274 3/20 0.39
ADORA1 P30542 3/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
CYP2A6 P11509 1/20 0.39
SMPD3 Q9NY59 1/20 0.39
METAP1 P53582 1/20 0.38
SYK P43405 5/20 0.37
CYP1A1 P04798 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP1B1 Q16678 3/20 0.36
SRC P12931 2/20 0.36
ZAP70 P43403 2/20 0.36
ADRB2 P07550 1/20 0.36
SPHK2 Q9NRA0 1/20 0.36
SPHK1 Q9NYA1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330575 0.98 HSP90AA1 (0.44) HSP90AA1PDPK1RAB9AADORA2AADORA1
SCHEMBL28550298 0.78 ADORA2A (0.37) HSP90AA1PDPK1RAB9AADORA2AADORA1
SCHEMBL5463009 0.77 PDPK1 (0.33) HSP90AA1PDPK1RAB9AADORA2AADORA1
SCHEMBL30511083 0.72
SCHEMBL18210540 0.71 HSP90AA1 (0.49) HSP90AA1PDPK1RAB9AADORA2AADORA1
SCHEMBL1673128 0.69
SCHEMBL102331 0.69 PDPK1 (0.59) HSP90AA1PDPK1RAB9AADORA2AADORA1
SCHEMBL4902877 0.68 RAB9A (0.61) HSP90AA1PDPK1RAB9ALOXL2CYP2A6
Aminothiazole SCHEMBL9354394 0.68 ALDH1A1 (0.54) HSP90AA1RAB9A
SCHEMBL1389231 0.68 HSP90AA1 (0.42) HSP90AA1PDPK1RAB9AADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190134140-A1 ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS BURCH LAURANELL HARRISON (US) 2019-05-09 US claimed
EP-1819721-A1 MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE Plant Bioscience Limited (GB) 2007-08-22 EP claimed
WO-2006054102-A1 MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE PLANT BIOSCIENCE LIMITED (GB) 2006-05-26 WO claimed
CN-114867724-B Process for preparing thiazolyl pyrazole carboxylic acid and intermediates thereof 班塔姆制药有限责任公司 2025-11-07 CN disclosed
US-20250326778-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS RIGEL PHARMACEUTICALS, INC. (US) 2025-10-23 US disclosed
EP-3976605-B1 METHODS FOR MAKING THIAZOLYLPYRAZOLE CARBOXYLIC ACIDS AND INTERMEDIATES THEREFOR BANTAM PHARMACEUTICAL LLC (US) 2025-08-20 EP disclosed
US-12378234-B2 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative BANTAM PHARMACEUTICAL, LLC (US) 2025-08-05 US disclosed
US-12378234-B2 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative BANTAM PHARMACEUTICAL, LLC (US) 2025-08-05 US disclosed
US-12358905-B2 Methods for making thiazolypyrazole carboxylic acids and intermediates therefor Bantam Pharamceutical, LLC (US) 2025-07-15 US disclosed
US-12358905-B2 Methods for making thiazolypyrazole carboxylic acids and intermediates therefor Bantam Pharamceutical, LLC (US) 2025-07-15 US disclosed
EP-3799871-B1 PYRAZOL-3-ONES THAT ACTIVATE PRO-APOTOTIC BAX DANA FARBER CANCER INST INC (US) 2024-02-28 EP disclosed
WO-2004045001-A2 ORGANIC LIGHT EMITTING MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2004-05-27 WO disclosed
US-20040091738-A1 Organic light emitting materials and devices UNIVERSAL DISPLAY CORPORATION 2004-05-13 US disclosed
CN-1492874-A Macrolide antibiotics 2004-04-28 CN disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1383747-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2004-01-28 EP disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2003008412-A2 HETERO-BICYCLIC CRF ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-01-30 WO disclosed
WO-2002088095-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2002-11-07 WO disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326778-A1 PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS IRAK3, IRAK1, IRAK2 HSP90AA1 4192/4885PDPK1 94/4885RAB9A 3229/4885
US-12358905-B2 Methods for making thiazolypyrazole carboxylic acids and intermediates therefor ABAT, WEE1, HADHB HSP90AA1 2675/4885PDPK1 573/4885RAB9A 3849/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 HSP90AA1 1034/4885PDPK1 4231/4885RAB9A 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.